Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Rizzello

Showing results (131-140 of 138) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 138 results.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 31, 2024
Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD)Gaetano Bergamaschi, Fabiana Castiglione, Renata D'Incà, et al.
Inflammatory Bowel Diseases|April 2, 2022
Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational StudyGaetano Bergamaschi, Fabiana Castiglione, Renata D'Incà, et al.
Journal of Crohn'S & Colitis|August 17, 2019
Separation of Low- Versus High-grade Crohn's Disease-associated Small Bowel Carcinomas is Improved by Invasive Front Prognostic Marker AnalysisGiovanni Arpa, Federica Grillo, Paolo Giuffrida, et al.
The American Journal of Gastroenterology|February 18, 2026
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD StudyFranco Scaldaferri, Federica Di Vincenzo, Marina Aloi, et al.
Annals of Surgical Oncology|August 8, 2020
Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel AdenocarcinomasAlessandro Vanoli, Federica Grillo, Camilla Guerini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 13, 2025
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Nicola Cersullo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 19, 2020
PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instabilityPaolo Giuffrida, Giovanni Arpa, Federica Grillo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 6, 2020
Correction: PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instabilityPaolo Giuffrida, Giovanni Arpa, Federica Grillo, et al.
Pageof 14

Showing results (131-140 of 138) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 138 results.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 31, 2024
Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD)Gaetano Bergamaschi, Fabiana Castiglione, Renata D'Incà, et al.
Inflammatory Bowel Diseases|April 2, 2022
Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational StudyGaetano Bergamaschi, Fabiana Castiglione, Renata D'Incà, et al.
Journal of Crohn'S & Colitis|August 17, 2019
Separation of Low- Versus High-grade Crohn's Disease-associated Small Bowel Carcinomas is Improved by Invasive Front Prognostic Marker AnalysisGiovanni Arpa, Federica Grillo, Paolo Giuffrida, et al.
The American Journal of Gastroenterology|February 18, 2026
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD StudyFranco Scaldaferri, Federica Di Vincenzo, Marina Aloi, et al.
Annals of Surgical Oncology|August 8, 2020
Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel AdenocarcinomasAlessandro Vanoli, Federica Grillo, Camilla Guerini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 13, 2025
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Nicola Cersullo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 19, 2020
PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instabilityPaolo Giuffrida, Giovanni Arpa, Federica Grillo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 6, 2020
Correction: PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instabilityPaolo Giuffrida, Giovanni Arpa, Federica Grillo, et al.
Pageof 14